Reduced item set for the amyotrophic lateral sclerosis assessment questionnaire: development and validation of the ALSAQ-5

C Jenkinson, R Fitzpatrick

Abstract

Objective—The 40 item amyotrophic lateral sclerosis assessment questionnaire (ALSAQ-40) is a subjective health measure designed specifically to assess areas of importance to patients with ALS. It was designed for use in surveys and clinical trials of this patient group, and has been assessed for reliability and validity. Despite its relative brevity there are situations where an even shorter form of the instrument would be desirable. Consequently, this paper reports a process of item reduction which results in a brief five item version of the instrument.

Methods—Data from two surveys of patients with ALS who completed the ALSAQ-40 were analysed to develop a short form ALSAQ. Questionnaire items were correlated with their dimension total scores. Highly correlated items were transformed onto a scale from 0 to 100 and results compared with the parent dimension.

Results—Five items were selected that produced results that closely resembled those of the five dimension scores of the ALSAQ-40.

Conclusions—Results on the new measure compared with the parent ("gold standard") ALSAQ-40 suggest that the measure can produce similar results to the longer form but with considerable economy.

(*J Neurol Neurosurg Psychiatry* 2001;70:70-73)

Keywords: amyotrophic lateral sclerosis specific measure; health status; ALSAQ-40; ALSAQ-5

The impacts of amyotrophic lateral sclerosis (ALS) are substantial, but until recently no disease specific measure had been available to systematically assess the consequences of the condition upon aspects of health status considered important by patients. Generic measures, such as the popular 36 item short form health survey (SF-36) have been used with this patient group¹ but disease specific measures have the advantage over generic measures in that they assess areas of particular salience to patients and are likely to be sensitive to changes which are central to their concerns.² The introduction of the 40 item ALS assessment questionnaire (ALSAQ-40) has made available for the first time a rigorously designed and validated subjective health status measure that can be used to evaluate the impact of treatment regimes on patients.

The ALSAQ-40 questionnaire was designed on the basis of in depth interviews with patients, which generated a large initial list of questionnaire items from which a 78 item measure was developed. This instrument was evaluated in surveys of patients with ALS. Statistical analysis of these data produced a final 40 item questionnaire. This contains five dimensions of subjective health status: physical mobility, activities of daily living and independence, eating and drinking, communication, and emotional reactions. The psychometric properties of the measure, together with a copy of the scale, have been documented in full.³

Despite the relative brevity of the ALSAQ-40 there are situations in which an even shorter instrument is desirable. Certainly, in the case of large scale trials it has been suggested that there is a greater chance of patient and physician participation when the data required are simple to collect and relatively brief. Indeed, the quality of recorded data in trials often suffers when too many data are collected on each patient.⁴ Furthermore, it is evidently desirable to reduce patient burden in data collection, especially when the demands of the illness can be considerable, as in neurological disorders such as ALS. The purpose of this paper, therefore, is to report on the development of a short form ALSAQ which may be used in large scale studies when the ALSAQ-40 is thought to be unpracticable.

Many attempts to reduce the length of instruments ignore, or at least do not report, appropriate methodological and statistical procedures.⁵ Most importantly, the choice of instrument for item reduction is usually inappropriate because there is little or no evidence for the reliability and validity of the original measure. Manifestly reducing the length of an instrument that is unreliable is not a worthwhile exercise. In this instance the ALSAQ-40 has proved validity and reliability and consequently is used as the "gold standard" for consequent item reduction. Results on any short form should produce results that are as close as possible to those of the long form. This paper documents the methods used to select items for a shorter version of the ALSAQ-40 and compares results between the two versions of the instrument.

Methods

MOTOR NEURON DISEASE ASSOCIATION SURVEY
Items for inclusion in the shortened form of the ALSAQ were derived from a data set that included the ALSAQ-40. This was a survey of the needs of patient members of the MND

**Picker Institute
Europe, King's Mead
House, Oxpens Road,
Oxford OX1 1JX, UK**
C Jenkinson

**Health Services
Research Unit,
Department of Public
Health, University of
Oxford, Institute of
Health Sciences,
Headington, Oxford,
OX3 7LF, UK**
C Jenkinson

**Department of Public
Health**
R Fitzpatrick

Correspondence to:
Dr C Jenkinson
crispin.jenkinson@
dphpc.ox.ac.uk

Received 2 June 2000
Accepted 16 August 2000

Table 1 Descriptive statistics for the five ALSAQ-40 domains and individual items (standardised to a score of 0–100)

Variable name	n	25th percentile	Median	75th percentile	Mean (SD)
Physical mobility*	144	52.5	71.25	100	69.88 (26.78)
MOB-1	146	50	75	100	72.43 (33.70)
MOB-2	146	0	50	100	54.62 (41.83)
MOB-3	146	50	75	100	63.36 (35.25)
MOB-4	145	25	75	100	62.24 (37.16)
MOB-5	146	75	100	100	81.34 (26.23)
MOB-6	146	75	75	100	77.23 (27.37)
MOB-7	146	0	75	100	57.36 (41.75)
MOB-8	146	75	100	100	85.45 (23.99)
MOB-9	146	50	75	100	71.58 (29.31)
MOB-10	145	50	75	100	76.03 (26.98)
ADL/Independence*	142	47.5	72.5	97.5	69.42 (26.41)
ADL-11	146	50	75	100	69.01 (29.70)
ADL-12	145	50	75	100	72.59 (29.80)
ADL-13	146	50	75	100	73.63 (26.87)
ADL-14	146	50	75	100	64.04 (33.73)
ADL-15	146	50	75	100	71.92 (32.28)
ADL-16	146	75	100	100	84.42 (22.39)
ADL-17	145	25	50	100	54.83 (39.67)
ADL-18	145	25	75	100	60.00 (39.35)
ADL-19	145	50	100	100	78.10 (27.46)
ADL-20	145	50	75	100	66.55 (36.94)
Eating and drinking*	145	0	33.33	62.5	37.93 (32.73)
EAT-21	145	0	50	75	41.21 (33.53)
EAT-22	145	0	25	75	39.14 (36.78)
EAT-23	145	0	25	50	33.45 (34.89)
Communication*	144	7.14	53.57	92.86	50.30 (40.58)
COM-24	145	0	50	100	48.45 (41.38)
COM-25	145	0	50	100	50.86 (42.02)
COM-26	145	0	50	100	46.21 (43.43)
COM-27	145	0	50	100	52.59 (43.87)
COM-28	144	0	75	100	55.38 (43.87)
COM-29	145	0	50	100	51.21 (44.42)
COM-30	145	0	50	100	49.14 (44.04)
Emotional reactions*	143	32.5	50	70	50.59 (24.88)
EM-31	145	0	50	75	41.55 (35.99)
EM-32	145	0	50	75	43.62 (33.17)
EM-33	147	25	50	75	48.30 (35.31)
EM-34	147	25	50	75	53.23 (32.88)
EM-35	147	50	75	100	63.61 (29.58)
EM-36	147	0	50	75	42.35 (35.43)
EM-37	147	25	50	75	46.26 (36.47)
EM-38	145	25	50	75	46.55 (29.85)
EM-39	147	50	75	100	64.46 (28.21)
EM-40	147	25	50	100	58.16 (34.27)

Bold indicates items selected for ALSAQ-5.

*Scale score from full 40 item ALSAQ-40.

Table 2 Descriptive statistics for the five dimensions of the ALSA-40 and ALSAQ-5 (denoted by the prefix "mini") for the MND Association and MND regional surveys

	Mean (SD)	95% CI	n
MND Association survey:			
Physical mobility	69.88 (26.78)	65.5–74.3	144
Mini-MOB	71.58 (29.31)	66.8–76.4	146
ADL/independence	69.42 (26.41)	65.0–73.8	142
Mini-ADL	69.01 (29.70)	64.2–73.9	146
Eating and drinking	37.93 (32.72)	32.6–43.3	145
Mini-EAT	39.14 (36.78)	33.1–45.2	145
Communication	50.30 (40.58)	43.6–57.0	144
Mini-COM	50.86 (42.02)	44.0–57.8	145
Emotional reactions	50.59 (24.88)	46.5–54.7	143
Mini-EM	53.23 (32.88)	47.9–58.6	147
MND Regional survey:			
Physical mobility	67.84 (28.63)	63.5–72.2	168
Mini-MOB	66.81 (34.81)	64.6–69.1	171
ADL/independence	69.39 (28.23)	65.1–73.7	168
Mini-ADL	72.11 (30.72)	67.5–76.7	173
Eating and drinking	39.42 (32.04)	34.6–44.3	171
Mini-EAT	40.70 (35.77)	35.3–46.1	172
Communication	49.37 (38.32)	43.6–55.2	169
Mini-COM	48.11 (42.32)	41.7–54.5	172
Emotional reactions	48.04 (26.40)	44.0–52.0	170
Mini-EM	50.44 (34.45)	45.2–55.6	171

Association of the United Kingdom which also included the ALSAQ-40 and questions on demographic details. Patients were excluded from this survey if they had an uncertain diagnosis or were close to death. Consequently, 250 of the remaining members were randomly selected from the MND Association database

and received the questionnaire together with a covering letter from the MND Association. No follow up was undertaken, as it was possible that people may die between the mailings and a repeat questionnaire from the MND Association could cause distress to relatives.

MOTOR NEURON DISEASE REGIONAL SURVEY

The results gained from the MND Association survey were compared with those of another large scale survey which included the ALSAQ-40 and the SF-36.⁶ The SF-36 is a generic measure which can yield two summary scores—the physical component summary (PCS) score and the mental component summary (MCS) scores.⁷ Results on the ALSAQ-40 and the shortened form ALSAQ were compared with results on the PCS/MCS. These data came from a postal survey in which care advisors for regions of the Motor Neuron Disease Association Society in England, Wales, and Northern Ireland were approached for help in recruiting. They provided names and addresses of patients with ALS/MND. However, a few patients (n=25) were not contacted in this way but volunteered to take part in the study, which had been outlined in a copy of *Thumbprint*, the United Kingdom MND Association newsletter. Including these 25 people the questionnaire was mailed to a total of 208 patients.

STATISTICAL ANALYSES

The MND association survey was used to determine which items should be included in a shortened version of the ALSAQ. Scores were calculated for the five dimensions of the ALSAQ-40, on a standard scale of 0 (best possible health state measured by the ALSAQ) to 100 (worst possible health state measured by the ALSAQ). Furthermore, all 40 items on the questionnaire were transformed onto a scale from 0 to 100, and each item compared with its dimension total. Items with mean scores not found to be significantly different from their scale total, and which most closely reflected the distribution of the scale were selected for inclusion in the short form measure; 95% confidence intervals (95% CIs) were calculated for each scale and item representing the scale in the short form five item ALSAQ (referred to here as ALSAQ-5). Each selected item was then correlated with the five scale scores, to ensure that it was both highly associated with the (uncorrected) scale score to which it contributes, and, further, was less well correlated with the other four scales.

The operating characteristics of the two measures was then assessed on the MND regional survey. Firstly, correlations of items to scale scores were undertaken again on this dataset to corroborate the results found from the MND Association survey. The ALSAQ-40 and ALSAQ-5 scores were then correlated with the SF-36 PCS and MCS to determine whether a similar pattern of associations was seen. It was hypothesised that if the operating characteristics of the two versions of the instrument are similar then the patterns of correlations between ALSAQ-5 items and the

Table 3 Correlations (Spearman) of ALSAQ-5 items (denoted by prefix "Mini") with dimensions of the ALSAQ-40 for the MND association survey

	Mini-mob	Mini-ADL	Mini-eat	Mini-com	Mini-em
Physical mobility	0.81** n=144	0.32** n=141	0.06 n=141	0.05 n=141	0.10 n=143
ADL/independence	0.62** n=142	0.79** n=142	0.18* n=141	0.09 n=142	0.14 n=142
Eating and drinking	0.02 n=143	0.09 n=143	0.95** n=145	0.71** n=144	0.33** n=144
Communication	0.03 n=142	0.06 n=142	0.63** n=143	0.94** n=144	0.38** n=144
Emotional reactions	0.11 n=141	0.11 n=141	0.34** n=142	0.41** n=143	0.85** n=143

Bold indicates correlation of parent scale with item.

Table 4 Correlations (Spearman) of ALSAQ-5 items (denoted by prefix "Mini") with dimensions of the ALSAQ-40 for the MND regional survey

	Mini-Mob	Mini-ADL	Mini-eat	Mini-com	Mini-Em
Physical mobility	0.84** n=168	0.34** n=168	0.10 n=167	0.12 n=166	0.25** n=165
ADL/independence	0.56** n=167	0.84** n=168	0.11* n=168	0.11 n=172	0.23** n=166
Eating and drinking	0.09 n=169	0.06 n=170	0.94** n=171	0.72** n=169	0.24** n=1168
Communication	0.15 n=168	0.03 n=169	0.68** n=168	0.93** n=169	0.28** n=166
Emotional reactions	0.27** n=167	0.14 n=169	0.36** n=171	0.25** n=168	0.83** n=170

Bold indicates correlation of parent scale with item.

PCS and MCS should closely resemble the pattern of correlations found between the dimensions of the ALSAQ-40 and the PCS and MCS.

Results

MOTOR NEURON DISEASE ASSOCIATION SURVEY

One hundred and forty nine (59.6%) of the questionnaires were returned. Ninety seven (65.1%) of the respondents were men and 52 (34.9%) were women. The mean age of respondents was 62.38 (SD 12.65) years (youngest 28, oldest 89 years). Twenty nine (19.5%) respondents had had the diagnosis of MND/ALS for 2 years or less, whereas 89 (59.8%) had had their diagnosis for 5 years or less. Seventy respondents (47.0%) indicated they had received help from someone else to complete the questionnaire. Five items were found to produce results, once standardised to the 0–100 scoring system of the parent questionnaire, which produced very similar descriptive statistics to the five respective scales from which they were extracted (table 1); 95% confidence intervals were calculated which

Table 5 Correlation (Spearman) of ALSAQ-40 dimensions and ALSAQ-5 items (denoted by prefix "Mini") with SF-36 mental component summary score (MCS) and SF-36 physical component summary score (PCS)

	MCS	PCS
Physical mobility	−0.15, n=62	−0.46, n=62**
Mini-MOB	−0.09, n=62	−0.33, n=62**
ADL/independence	0.16, n=62	−0.39, n=62**
Mini-ADL	0.05, n=62	−0.31, n=62**
Eating and drinking	−0.28, n=62*	−0.01, n=62
Mini-EAT	−0.27, n=62*	−0.04, n=62
Communication	−0.40, n=61*	0.03, n=61
Mini-COM	−0.30, n=62*	0.03, n=62
Emotional reactions	−0.70, n=60***	−0.12, n=60
Mini-EM	−0.63, n=60***	−0.05, n=62

*Correlation significant at the 0.05 level; **Correlation significant at the 0.01 level; ***Correlation significant at the 0.01 level.

indicated that the item scores overlapped considerably with the scale scores (table 2).

The five selected items of the ALSAQ-5 were correlated with all five dimensions scores on the ALSAQ-40 (table 3). Items were found to be correlated the most highly with the parent dimension from which they were extracted.

MOTOR NEURON DISEASE REGIONAL SURVEY

A response rate of 173 (83.2%) was achieved. The mean age of the sample was 62.6 (SD 12.5) years (youngest 31, oldest 92, n=168). Sixty six (38.2%) of the sample were women and 104 (60.1%) men. Eighty nine (53%) respondents reported that they had had the diagnosis of MND/ALS for 2 years or less, whereas 140 (83.3%) had had their diagnosis for 5 years or less. Eighty one respondents

Table 6 Dimensions and items of the ALSAQ-40 and ALSAQ-5 (in italics)

Scale	Item No on ALSAQ-40	Items
Physical mobility (MOB):		
	1	Difficulty walking short distances
	2	Fallen whilst walking
	3	Stumbled or tripped whilst walking
	4	Lost balance whilst walking
	5	Concentrate when walking
	6	Tired when walking
	7	Pains in legs whilst walking
	8	Difficulty going up and down stairs
	9	Difficulty standing up
	10	Difficulty getting up out of chairs
Adl/independence (ADL):		
	11	Difficulty using arms and hands
	12	Difficulty turning and moving in bed
	13	Difficulty picking things up
	14	Difficulty holding books and turning pages
	15	Difficulty writing clearly
	16	Difficulty doing jobs around the house
	17	Difficulty feeding myself
	18	Difficulty combing hair
	19	Difficulty getting dressed
	20	Difficulty washing at hand basin
Eating and drinking (EAT):		
	21	Difficulty swallowing
	22	Difficulty eating solid food
	23	Difficulty drinking liquids
Communication (COM):		
	24	Difficulty participating in conversations
	25	Speech not easy to understand
	26	Slurred or stuttered whilst speaking
	27	Have to talk slowly
	28	Talked less than I used to do
	29	Frustrated by speech
	30	Felt self conscious about speech
Emotional reactions (EM):		
	31	Felt lonely
	32	Felt bored
	33	Felt embarrassed in social situations
	34	Felt hopeless about the future
	35	Worried that I was a burden to others
	36	Wondered why I kept going
	37	Felt angry because of the disease
	38	Felt depressed
	39	Worried how disease will affect my future
	40	Felt as if I had no freedom

(46.0%) indicated that they had received help from someone else to complete the questionnaire. Mean scores on the five dimensions of the ALSAQ-40 and the five items of the ALSAQ-5 were computed (table 2). No significant differences were found between the scores when both were standardised onto a scale of 0–100. The five selected items of the ALSAQ-5 were correlated with all five dimension scores on the ALSAQ-40. Once again, items were found to be correlated the most highly with their parent dimension (table 4).

Results on the ALSAQ-5 and ALSAQ-40 were correlated with the SF-36 PCS and MCS summary scores (table 5). Similar magnitudes of correlation were found with the summary scores whether they were correlated with the ALSAQ-40 dimensions or ALSAQ-5 items. This suggests that the operating characteristics of the ALSAQ-5 items are similar to those of the ALSAQ-40-dimensions. The five items selected for inclusion in the ALSAQ-5, as well as the 40 items of the original questionnaire, are shown in table 6.

Discussion

Amyotrophic lateral sclerosis has substantial consequences in terms of impairment and disability. Those with the disorder may experience wide ranging adverse effects to their quality of life. Until recently systematic attempts to assess ALS have focused on standardising clinical findings and ratings of symptoms.⁸ However, all such scales are limited in that observer based rating scales may relate only weakly to the patients' experience of the disease. The development of an ALS specific measure allows for a more complete picture of the impact of the disease on patients' lives. The ALSAQ-40 has been shown to have high levels of reliability and validity and as such should be a valuable addition to outcomes assessment in this area. However, even a relatively brief instrument such as the ALSAQ-40 is not practicable for all purposes. To this end one item was selected from each dimension which most closely duplicates the results gained from the multi-item scale score, but does so with considerable economy. The very high levels of internal reliability of the original scales would suggest that each is tapping a meaningful underlying construct, and the close association of results on the five items of the ALSAQ-5 with their respective dimension on the ALSAQ-40 would suggest that the shortened instrument is providing a similar picture of the disease. The ALSAQ-5 would therefore seem to be a useful measure for surveys or trials in which a short disease specific measure is

needed. There is less evidence that the instrument would be useful to assess health status over time at the level of the individual patient in an accurate manner. However, it may prove a useful adjunct to the clinical interview in a similar way that the COOP charts⁹ have been suggested as useful in general practice.¹⁰ The COOP charts consist of nine items. Each item is related to a health related area of wellbeing, such as emotional wellbeing, social functioning, mobility, etc. The Dartmouth Group suggest that these measures can be handed out in busy clinicians' waiting rooms and be rapidly and easily completed by patients. The charts are then returned to the physician. No scoring algorithms are required and physicians can directly ask questions relating to what is completed on the cards. It has been suggested that such simple methods can dramatically influence doctor-patient communication.¹¹ It is possible that the ALSAQ-5 may also find this use. Further research is required in this area to determine how useful such data presented to clinicians would really be, and also to assess the reliability of single items for use in this manner.

The ALSAQ-5 provides a brief assessment of the impacts of ALS/MND upon patients which closely reflects results of the longer form ALSAQ-40. In instances where the 40 item measure is regarded as not practicable then the ALSAQ-5 may be the instrument of choice. Copies of the instrument are available from CJ.

- 1 Jenkinson C, Swash M, Fitzpatrick R, *et al.* The European amyotrophic lateral sclerosis health profile study. *J Neurol Sci* 1998;160(suppl 1):122–6.
- 2 Jenkinson C, Fitzpatrick R, Brennan C, *et al.* Development and validation of short measure of health status for individuals with ALS/MND: The ALSAQ-40. *J Neurol* 1999;246(suppl 3):16–21.
- 3 Jenkinson C, Fitzpatrick R, Brennan C, *et al.* Evidence for the validity and reliability of the ALS assessment questionnaire: the ALSAQ-40. *Amyotrophic Lateral Sclerosis and Other Motor Neurone Diseases* 1999;1:33–40.
- 4 Pocock SJ. *Clinical trials: a practical approach*. Chichester: John Wiley, 1983.
- 5 Coste J, Guillemin F, Pouchot J, *et al.* Methodological approaches to shortening composite measurement scales. *J Clin Epidemiol* 1997;50:247–52.
- 6 Jenkinson C, Fitzpatrick R, Levy G, *et al.* The ALSAQ-40. Tests of data quality, score reliability and response rate in a survey of patients. *J Neurol Sci* (in press).
- 7 Ware JE, Kosinski M, Keller S. *SF-36 Physical and mental health summary scales: a user manual*. Boston, Massachusetts: The Health Institute, New England Medical Center, 1994.
- 8 Jenkinson C, Fitzpatrick R, Swash M. Amyotrophic lateral sclerosis/motor neurone disease. In: Jenkinson C, Fitzpatrick R, Jenkinson D. *Health status measurement in neurological disorders*. Oxford: Radcliffe Medical Press, 2000.
- 9 Beaufait DW, Nelson EC, Landgraf JM, *et al.* COOP measures of functional status. In: Stewart M, Tudiver F, Bass MJ, *et al.*, eds. *Research methods for primary care*. Vol 2. *Tools for primary care research*. London: Sage, 1992.
- 10 Nelson EC, Landgraf JM, Hays RD, *et al.* The functional status of patients: how can it be measured in physicians' offices? *Med Care* 1990;28:1111–26.
- 11 Wasson J, Keller A, Rubenstein L, *et al.* Benefits and obstacles of health status assessment in ambulatory settings: the clinicians point of view. *Med Care* 1992;30(suppl):MS42–9.